HanAll Biopharma
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
HanAll Biopharma Reports Full-Year 2022 Results and Provides Business Update 2023-02-01 20:00
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update 2022-11-15 20:00
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab 2022-10-11 19:00
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner 2022-10-04 19:00
HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update 2022-07-29 20:00
HanAll Biopharma Reports First Quarter 2022 Results and Provides Business Update 2022-04-28 19:00
1 2